174 related articles for article (PubMed ID: 14740953)
1. Atypical antibody responses in dengue vaccine recipients.
Kanesa-Thasan N; Sun W; Ludwig GV; Rossi C; Putnak JR; Mangiafico JA; Innis BL; Edelman R
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):32-8. PubMed ID: 14740953
[TBL] [Abstract][Full Text] [Related]
2. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
3. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
J Virol; 2020 May; 94(10):. PubMed ID: 32132233
[TBL] [Abstract][Full Text] [Related]
4. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
Sun W; Edelman R; Kanesa-Thasan N; Eckels KH; Putnak JR; King AD; Houng HS; Tang D; Scherer JM; Hoke CH; Innis BL
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):24-31. PubMed ID: 14740952
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
[TBL] [Abstract][Full Text] [Related]
7. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
[TBL] [Abstract][Full Text] [Related]
8. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
9. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
10. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey].
Ergünay K; Saygan MB; Aydoğan S; Litzba N; Niedrig M; Pınar A; Us D
Mikrobiyol Bul; 2010 Jul; 44(3):415-24. PubMed ID: 21063991
[TBL] [Abstract][Full Text] [Related]
12. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
Sun W; Cunningham D; Wasserman SS; Perry J; Putnak JR; Eckels KH; Vaughn DW; Thomas SJ; Kanesa-Thasan N; Innis BL; Edelman R
Hum Vaccin; 2009; 5(1):33-40. PubMed ID: 18670195
[TBL] [Abstract][Full Text] [Related]
14. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
15. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC
PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748
[TBL] [Abstract][Full Text] [Related]
16. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.
Kanesa-Thasan N; Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Coster TS; Kim-Ahn GJ; Dubois DR; Putnak JR; King A; Summers PL; Innis BL; Eckels KH; Hoke CH
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):17-23. PubMed ID: 14740951
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
Edelman R; Wasserman SS; Bodison SA; Putnak RJ; Eckels KH; Tang D; Kanesa-Thasan N; Vaughn DW; Innis BL; Sun W
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):48-60. PubMed ID: 14740955
[TBL] [Abstract][Full Text] [Related]
19. Mechanism and significance of cell type-dependent neutralization of flaviviruses.
Mukherjee S; Dowd KA; Manhart CJ; Ledgerwood JE; Durbin AP; Whitehead SS; Pierson TC
J Virol; 2014 Jul; 88(13):7210-20. PubMed ID: 24741083
[TBL] [Abstract][Full Text] [Related]
20. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
